Sargazi Nasrin, Takian Amirhossein, Yaseri Mehdi, Daroudi Rajabali, Ghanbari Motlagh Ali, Nahvijou Azin, Zendehdel Kazem
Department of Health Management, Policy and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran (TUMS), Iran.
Department of Global Health and Public Policy, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Prev Med Rep. 2021 Jun 6;23:101438. doi: 10.1016/j.pmedr.2021.101438. eCollection 2021 Sep.
This study aimed to identify mothers' preferences and willingness-to-pay (WTP) for human papillomavirus (HPV) vaccines (in this case, bivalent and quadrivalent) in Iran. We used a discrete choice experiment (DCE) method to present mothers with choices between two hypothetical profiles of vaccines, described by combinations of five attributes, each with two or three levels. We analyzed the DCE results using conditional logistic regression and measured WTP estimates for each attribute. Our response rate was 53.96%, while the completion rate for questioner was 93.57%. We identified protection against cervical cancer, protection against genital warts, protection duration, serious side effects, and cost to influence mothers' preferences for HPV vaccination. The relative importance for serious side effects was the highest among all attributes. Mothers' WTP for bivalent and quadrivalent HPV vaccines was in US $ -432 (US $1 = IRR 42,000) and US $ 380, respectively. Quadrivalent vaccination could be the most suitable candidate for implementing the national immunization schedule. The reason is that mothers express more WTP for the quadrivalent vaccine than bivalent due to its protection against genital warts.
本研究旨在确定伊朗母亲们对人乳头瘤病毒（HPV）疫苗（在本研究中为二价和四价疫苗）的偏好及支付意愿（WTP）。我们采用离散选择实验（DCE）方法，向母亲们展示两种假设的疫苗情况供其选择，这些情况由五个属性的组合描述，每个属性有两个或三个水平。我们使用条件逻辑回归分析DCE结果，并测量每个属性的支付意愿估计值。我们的回复率为53.96%，而问卷完成率为93.57%。我们确定预防宫颈癌、预防尖锐湿疣、保护期限、严重副作用以及成本会影响母亲们对HPV疫苗接种的偏好。在所有属性中，严重副作用的相对重要性最高。母亲们对二价和四价HPV疫苗的支付意愿分别为-432美元（1美元 = 42,000伊朗里亚尔）和380美元。四价疫苗接种可能是实施国家免疫计划最合适的选择。原因是由于四价疫苗可预防尖锐湿疣，母亲们对其表达出比对二价疫苗更高的支付意愿。
